Search

Displaying results 3891 - 3900 of 5302 in total
  1. Drug

    N-(3-carboxypropanoyl)-L-norvaline

    go.drugbank.com/drugs/DB08554
    Experimental

    These are compounds containing an alpha amino acid which bears an acyl group at his terminal nitrogen atom.

  2. Drug

    Bectumomab

    go.drugbank.com/drugs/DB04962
    Experimental

    Bectumomab (marketed under the trade name LymphoScan®) is a mouse monoclonal antibody and which it's used to treat non-Hodgkin's lymphoma. It has a radioisotope, technetium (99m TC) which it's added.

  3. Drug

    Zinc glycinate

    go.drugbank.com/drugs/DB14493
    Investigational

    Glycoprotein marker of gastrointestinal cancer.

    Mixtures: vitaMedMD Rx Plus
  4. Drug

    Tusamitamab ravtansine

    go.drugbank.com/drugs/DB17448
    Investigational

    Tusamitamab ravtansine is an antibody-drug conjugate that targets carcinoembryonic antigen-related cell adhesion molecule-5 (CEACAM5).

  5. Drug

    Crefmirlimab

    go.drugbank.com/drugs/DB17577
    Investigational

    Crefmirlimab is an anti-human CD8 probe targeting the CD8 antigen, for the diagnosis of various cancers.

  6. Drug

    PYX-201

    go.drugbank.com/drugs/DB18382
    Investigational

    PYX-201 is an antibody-drug conjugate directed against the extra domain-B splice variant of fibronectin.

  7. Drug

    REN-850

    go.drugbank.com/drugs/DB05912
    Experimental

    REN-850 is an oral drug for multiple sclerosis which is in Phase I of clinical trials.

  8. Drug

    Lefradafiban

    go.drugbank.com/drugs/DB04863
    Investigational

    Lefradafiban is an oral platelet glycoprotein IIb/IIIa receptor antagonist being investigated in the treatment of angina.

  9. Drug

    D-Phenylalanine

    go.drugbank.com/drugs/DB02556
    Experimental

    An essential aromatic amino acid that is a precursor of melanin; dopamine; noradrenalin (norepinephrine), and thyroxine. [PubChem]

  10. Drug

    Eflapegrastim

    go.drugbank.com/drugs/DB15001
    ApprovedInvestigational

    [A252320] It typically develops during the first cycle of chemotherapy and is associated with an increased risk of morbidity and mortality. … as the co-occurrence of fever (temperature > 38 ◦C) and severe neutropenia (ANC < 500 cells/mm<sup>3</sup>), is a potential side effect of myelosuppressive chemotherapy in which the patient develops an